RxDoctor Payments Data

Luis Espinoza

Rheumatology · New Orleans, LANPI 1881616688

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $7,700 of the $11,437 with a category attached, or 67.3%. Pfizer accounts for 84.8% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2019 at $11,167 and has fallen 99.9% since, to $17 in 2024.

$11,437in general payments, 2019–2025

Across 140 payments — averaging $81.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$10K
  • Regeneron Healthcare Solutions, Inc.$364
  • GSK$312
  • AbbVie$239
  • Novartis$221
  • UCB, Inc.$129
  • plus $470 from 12 others

What the payments were for

  • Consulting fees$7,70067%
  • Travel & lodging$9508%
  • Food & beverage$2,78724%

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,437 in reported general payments places this provider in the 55th percentile of 88 rheumatology providers in Louisiana.

See all rheumatology providers in Louisiana

Other rheumatology in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →